These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35486279)

  • 1. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
    Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
    Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of sarpogrelate and dopamine D
    Fouad Shalaby MA; Abd El Latif HA; El Yamani M; Galal MA; Kamal S; Sindi I; Masaood R
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):64. PubMed ID: 34702339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
    Lamos EM; Levitt DL; Munir KM
    Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC; Appiah-Kubf LS; Chaudhuri KR
    Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
    Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
    Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.
    Chen H; Fu J; Huang W
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008883. PubMed ID: 27455388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bromocriptine: uses until now and prospects of new therapeutic applications].
    Górska D
    Neurol Neurochir Pol; 2000; 34(3):573-8. PubMed ID: 10979549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine therapy: Review of mechanism of action, safety and tolerability.
    Naz F; Malik A; Riaz M; Mahmood Q; Mehmood MH; Rasool G; Mahmood Z; Abbas M
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):903-922. PubMed ID: 35635035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
    Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
    J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinagolide--a valuable treatment option for hyperprolactinaemia.
    Barlier A; Jaquet P
    Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
    Krysiak R; Gilowski W; Szkrobka W; Okopien B
    Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
    Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
    Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
    Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.